R&D channel feed

Zymeworks sings to the tune of $325M with Jazz opt-in for HER2 can­cer drug

3 years ago
Deals

Celyad scraps one fi­nal clin­i­cal CAR-T pro­gram as clock ticks

3 years ago
Cell/Gene Tx

Blam­ing place­bo re­sponse for 'un­in­ter­pretable' PhI­II re­sults, Con­tra­Fect calls for new an­tibi­ot­ic study

3 years ago

Verona says sec­ond PhI­II for COPD drug hits the mark, plans 2023 NDA fil­ing

3 years ago

Cat­a­lyst Phar­ma­ceu­ti­cals to ac­quire com­mer­cial rights to an Ei­sai seizure med­ica­tion for $160M

3 years ago
Deals

Ma­gen­ta's blood can­cer ADC faces two dose-lim­it­ing tox­i­c­i­ties, trig­ger­ing co­hort stop­page

3 years ago

Gilead and Ar­cus want you to be­lieve again in TIG­IT. But mixed ARC-7 da­ta are rolling out to a tough crowd

3 years ago
Bioregnum

Zymeworks shows pos­i­tive — yet ear­ly — piv­otal da­ta in bile duct can­cers, plans ac­cel­er­at­ed ap­proval run

3 years ago

Emerg­ing from he­pati­tis B flops, As­sem­bly Bio show­cas­es ear­ly da­ta on next-gen drugs

3 years ago

Pfiz­er opts in to net Lian­Bio’s rights to RSV can­di­date, putting down $20M up­front

3 years ago
Deals

FDA lifts hold on stud­ies of blue­bird's sick­le cell gene ther­a­py in ado­les­cents

3 years ago
Cell/Gene Tx

Madri­gal’s NASH drug wins on piv­otal PhI­II end­points, set­ting stage for ac­cel­er­at­ed ap­proval

3 years ago

Alzheimer's fail crush­es small biotech's share price to near­ly pen­ny stock

3 years ago

As­traZeneca's Imfinzi fails in lung can­cer tri­al as a monother­a­py to im­prove OS

3 years ago

#ASH22 Re­cap: Lead­ing hema­tol­ogy ex­perts talk top read­outs; Fire­side chat with No­vo Nordisk's Lu­dovic Helf­gott; More

3 years ago
Discovery
Cell/Gene Tx

Dr. Red­dy's sub­sidiary hits the pause but­ton on drug de­vel­op­ment for pso­ri­a­sis

3 years ago

Al­ny­lam's R&D up­date in­cludes 3 halts, Alzheimer's time­line and an­oth­er NASH

3 years ago

Scoop: As Sio clos­es, for­mer CEO from ‘vant ex­it finds him­self at helm of Irv Weiss­man stealth biotech

3 years ago
Startups

Eli Lil­ly and So­sei en­ter in­to di­a­betes and meta­bol­ic dis­ease deal, go­ing af­ter GPCR

3 years ago
Deals

BioN­Tech founder­s' on­col­o­gy start­up rolls up its sec­ond PhI­II win for Astel­las

3 years ago

De­bat­ing the p-val­ues be­hind Mod­er­na's $16B mar­ket-cap gain

3 years ago

Amid strep A out­break in the UK, gov­ern­ment watch­dog in­ves­ti­gates soar­ing an­tibi­ot­ic prices

3 years ago

Up­dat­ed: Maze re­veals pos­i­tive first look at PhI Pompe dis­ease can­di­date

3 years ago

Up­dat­ed: Tale of two ‘Abs’: Ab­b­Vie part­ners with an­ti­body biotech Ab­Cellera, but keeps de­tails un­der wraps

3 years ago
First page Previous page 105106107108109110111 Next page Last page
A service from the Financial Times